ReviewMikrochimica acta2020
Recent advances in aptamer-based sensors for breast cancer diagnosis: special cases for nanomaterial-based VEGF, HER2, and MUC1 aptasensors.
Review in Mikrochimica acta, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- FunctionalACS bio & med chem Au · 2025Article
- Impact of Nanomedicine in Women's Metastatic Breast Cancer.Small (Weinheim an der Bergstrasse, Germany) · 2024Review
- Gold nanostructure-enhanced immunosensing: ultra-sensitive detection of VEGF tumor marker for early disease diagnosis.Scientific reports · 2024Article
- DNA-Based Nanomaterials as Drug Delivery Platforms for Increasing the Effect of Drugs in Tumors.Cancers · 2023Review
- Aptamer-conjugated gold nanoparticles and their diagnostic and therapeutic roles in cancer.Frontiers in bioengineering and biotechnology · 2023Review
- Application of aptamer functionalized nanomaterials in targeting therapeutics of typical tumors.Frontiers in bioengineering and biotechnology · 2023Review
- Effects of Stellera chamaejasme on microvascular density and apoptosis of cancer cells in a rat bladder tumor model.Translational andrology and urology · 2022Article
- Recent advances in nanomaterials-based electrochemical immunosensors and aptasensors for HER2 assessment in breast cancer.Mikrochimica acta · 2021Review
- Breast Cancer Aptamers: Current Sensing Targets, Available Aptamers, and Their Evaluation for Clinical Use in Diagnostics.Cancers · 2021Review
- Recent Advances in Nanomaterial-Based Aptasensors in Medical Diagnosis and Therapy.Nanomaterials (Basel, Switzerland) · 2021Review
- A "signal off" aptasensor based on NiFeMikrochimica acta · 2021Article
- Identification of Prognostic Biomarkers and Molecular Targets Among JAK Family in Breast Cancer.Journal of inflammation research · 2021Article
- Electrochemical Aptasensors Based on Hybrid Metal-Organic Frameworks.Sensors (Basel, Switzerland) · 2020Review
- Aptamers for Proteins Associated with Rheumatic Diseases: Progress, Challenges, and Prospects of Diagnostic and Therapeutic Applications.Biomedicines · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer is one of the most common and important diseases with a high mortality rate. Breast cancer is among the three most common types of cancer in women, and the mortality rate has reached 0.024% in some countries. For early-stage preclinical diagnosis of breast cancer, sensitive and reliable tools are needed. Today, there are many types of biomarkers that have been identified for cancer diagnosis. A wide variety of detection strategies have also been developed for the detection of these biomarkers from serum or other body fluids at physiological concentrations. Aptamers are single-stranded DNA or RNA oligonucleotides and promising in the production of more sensitive and reliable biosensor platforms in combination with a wide range of nanomaterials. Conformational changes triggered by the target analyte have been successfully applied in fluorometric, colorimetric, plasmonic, and electrochemical-based detection strategies. This review article presents aptasensor approaches used in the detection of vascular endothelial growth factor (VEGF), human epidermal growth factor receptor 2 (HER2), and mucin-1 glycoprotein (MUC1) biomarkers, which are frequently studied in the diagnosis of breast cancer. The focus of this review article is on developments of the last decade for detecting these biomarkers using various sensitivity enhancement techniques and nanomaterials.
Indexed as
Identifiers
32888061What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.